Pleural Mesothelioma Patients with 5-Year Survival Still RareResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2021, April 22). Pleural Mesothelioma Patients with 5-Year Survival Still Rare. Asbestos.com. Retrieved February 8, 2023, from https://www.asbestos.com/news/2021/04/22/mesothelioma-5-year-survival/
Povtak, Tim. "Pleural Mesothelioma Patients with 5-Year Survival Still Rare." Asbestos.com, 22 Apr 2021, https://www.asbestos.com/news/2021/04/22/mesothelioma-5-year-survival/.
Povtak, Tim. "Pleural Mesothelioma Patients with 5-Year Survival Still Rare." Asbestos.com. Last modified April 22, 2021. https://www.asbestos.com/news/2021/04/22/mesothelioma-5-year-survival/.
Although no amount of asbestos exposure is considered safe, lower levels of non-occupational exposure are most often linked to long-term survival for those diagnosed with malignant pleural mesothelioma, according to a recent study.
Clinical Lung Cancer published the study that compared characteristics of 43 pleural mesothelioma patients who survived at least five years with the disease to a much larger control group.
Several previous mesothelioma studies have estimated that the five-year survival rate is just under 5% for pleural mesothelioma, an aggressive cancer with no definitive cure. It is caused almost exclusively by exposure to asbestos.
“The reasons for dismal long-term survival rates include diagnosis at late stage and poor response to conventional treatment modalities,” the authors wrote. “However, as some patients achieve prolonged survival, researchers have tried to identify prognostic factors underlying this phenomenon.”
Age, Sex and Exposure Matter in Mesothelioma Survival
Clinical factors of long-term survival were not surprising, and similar to less comprehensive studies. They included younger patients, more frequently female patients, a better performance status at the time of diagnosis and non-occupational exposure to asbestos.
The study was conducted by researchers mostly from the departments of pathology and pulmonary medicine at Helsinki University Hospital in Finland.
Researchers declined to provide additional perspective and insight to The Mesothelioma Center at Asbestos.com.
The original aim of the study was to evaluate diagnostic accuracy of long-term mesothelioma survivors, which often is questioned with this tough-to-diagnose cancer.
“Our hypothesis was, similar to an earlier study conducted with patients with pancreatic cancer, that not all of these [long-term survival] patients would represent mesothelioma, but rather had been misdiagnosed,” the authors wrote. “But contrary to our original hypothesis, the re-evaluation confirmed good diagnostic accuracy, suggesting a subtype with a better prognosis.”
The study also concluded that tumor size and first-line treatment were associated with survival time.
Finnish Study Included Epithelial Subtype
The study originated from a cohort of 1,010 patients from the Finnish Cancer Registry who were diagnosed with pleural mesothelioma. A subgroup of 43 long-term survivors were compared with a control group of 84 patients, all of whom had the most easily treated epithelial subtype of mesothelioma.
(at least 5 years)
|Median Overall Survival||79.3 months||11.3 months|
|Known Occupational Exposure||42%||75%|
|Stage 3 or 4 Disease at Diagnosis||33.3%||47.6%|
Smoking History Similar with Both Study Groups
Although smoking has been associated typically with shorter mesothelioma survival rates, it was not a factor in either group of patients in this study. In the long-term survival group, 44% said they had never smoked. In the control group with the much shorter median survival, 48% said the same.
Occupational exposure was documented from medical records. In Finland, employees are automatically entitled legally to receive compensation for an occupational disease.
A second malignancy type was found in 16% of the long-term survival group and 17% of the control group. There was no difference observed in the first-line treatment modality between the two groups.
By the end of the study period, 10 patients in the long-term survival group were still alive and three had died of causes other than pleural mesothelioma. None in the control group were still alive.
“The prolonged survival time is most likely explained by a combination of tumor-, patient- and treatment-related factors,” the authors concluded. “Although we found that surgery and chemotherapy were associated with longer survival, the role of radical intent surgery was insignificant.”